5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.33▲ | 2.34▼ | 2.33▼ | 2.42▼ | 2.38▼ |
MA10 | 2.33▼ | 2.33▲ | 2.34▼ | 2.43▼ | 2.70▼ |
MA20 | 2.33▲ | 2.36▼ | 2.41▼ | 2.43▼ | 3.10▼ |
MA50 | 2.36▼ | 2.43▼ | 2.46▼ | 3.00▼ | N/A |
MA100 | 2.43▼ | 2.46▼ | 2.39▼ | 3.13▼ | N/A |
MA200 | 2.45▼ | 2.41▼ | 2.58▼ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | 0.002▲ | -0.007▼ | 0.034▲ | 0.011▲ |
RSI | 47.420▼ | 38.069▼ | 39.221▼ | 40.432▼ | 37.627▼ |
STOCH | 36.905 | 50.654 | 29.189 | 45.936 | 9.060▼ |
WILL %R | -42.857 | -66.667 | -84.091▼ | -65.672 | -90.043▼ |
CCI | 0.000 | -42.017 | -60.421 | -51.145 | -86.165 |
Saturday, July 12, 2025 07:17 AM
Find the latest information on TuHURA Biosciences, Inc. Common Stock (HURA) insider activity and insider shares traded to make sound investments with Nasdaq.com.
|
Tuesday, July 01, 2025 05:49 AM
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that ...
|
Monday, June 30, 2025 05:50 AM
TAMPA, Fla., June 30, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
14/07/25 | 2.30 | 2.36 | 2.30 | 2.33 | 144,804 |
11/07/25 | 2.52 | 2.55 | 2.28 | 2.30 | 214,723 |
10/07/25 | 2.50 | 2.55 | 2.4458 | 2.52 | 239,745 |
09/07/25 | 2.48 | 2.52 | 2.4247 | 2.49 | 119,200 |
08/07/25 | 2.41 | 2.545 | 2.38 | 2.48 | 216,800 |
07/07/25 | 2.48 | 2.48 | 2.32 | 2.40 | 206,802 |
03/07/25 | 2.64 | 2.735 | 2.15 | 2.48 | 600,136 |
02/07/25 | 2.535 | 2.77 | 2.44 | 2.61 | 597,813 |
01/07/25 | 2.24 | 2.528 | 2.16 | 2.47 | 357,000 |
30/06/25 | 2.34 | 2.43 | 2.17 | 2.23 | 325,500 |
|
|
||||
|
|
||||
|
|